hCD19 CAR-T cells

hCD19 CAR-T cells are a form of autologous cell therapy in which a patient's own T lymphocytes are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the human CD19 antigen. CD19 is a protein expressed on the surface of most B-cell malignancies, including various types of lymphoma and leukemia. The "h" in hCD19 refers to the use of a fully human-derived single-chain variable fragment (scFv) as the targeting domain within the CAR construct, designed to reduce immunogenicity compared to murine or hybrid scFvs[3][5]. After engineering, these modified T-cells are expanded ex vivo and then infused back into the patient. Once administered, they recognize and bind to CD19-expressing malignant B-cells and mediate their destruction through cytotoxic immune mechanisms. This approach has shown high response rates in relapsed/refractory B-cell malignancies[3][5]. The therapy is considered highly personalized ("living drug") and represents an advanced form of adoptive cellular immunotherapy.

Other names

human CD19 chimeric antigen receptor T cellsCD19 CAR-T cellsCD-19 CAR-T cellsCD 19 CAR-T cellsfully human anti-CD19 CAR T cells